Ireland
--:--IST
Recruiting Not applicable

Role of Inferior Colliculi in Auditory Hallucinations

NCT07003529 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-09-12
Last updated
2025-12-09

Condition(s) studied

SchizophreniaHallucinations, Auditory

Investigational drug(s) / intervention(s)

Unenhanced brain MRI

Unenhanced brain MRI: Unenhanced brain MRI in five sequences: 1) T1-weighted anatomical sequences 2) Resting-state functional sequences 3) Task-based functional sequence 4) Structural sequence using Diffusion Tensor Imaging (DTI) 5) Routine magnetic resonance spectroscopy sequence

Study summary

The neural basis of auditory hallucinations (AH) in patients with schizophrenia is poorly characterized. Functional imaging studies investigate either the "state" dimension (i.e., the measurement of changes in brain area activation at the precise moment of AH onset) or the "trait" dimension (i.e., the neural correlates of the propensity to hallucinate). A corollary of AH (particularly acoustic-verbal) is the activation of brain regions involved in the auditory perception of speech (auditory cortex). One theory is that patients with schizophrenia with AH may have a deficit in processing their internal speech (i.e., external attribution to internal verbal content). However, there is little clinical data on the specific role of the mesencephalic region of the inferior colliculi (IC) in the formation of these symptoms. Preliminary research has shown intense expression of dopamine D2 receptors, particularly on glutamatergic neurons in mouse ICs. Thus, ICs receive numerous inhibitory dopaminergic inputs, likely involved in signal optimization and modulation. The study authors hypothesize that AHs are the result of a defect in signal inhibition by the IC, which lose their function as perceptual filters.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * DSM-5 diagnosis of schizophrenic disorder (based on clinical assessment and confirmed by the MINI 7.0 interview) * Patient with a schizophrenic disorder lasting ≤ 20 years * Patient treated in a psychiatric unit as an inpatient (in non-specialized care) or outpatient or under a mandatory ambulatory psychiatric care programme * Clinical condition compatible with imaging based on clinical judgment * Ability to understand, write, and read French Specific inclusion criteria for the group (SCZ+/HA+) • Patient with a PANSS score (question P3 regarding hallucinations) ≥ 4 (corresponds to PANSS (P3) 4, 5, 6, and 7 patients) AND having experienced hallucinations in the past 15 days. Specific inclusion criteria for the control group • Patient with a PANSS score (question P3 regarding hallucinations) = 1) AND having not experienced any hallucinations in the past 15 days. Exclusion Criteria: * The patient is under safeguard of justice or state guardianship * Contraindications to magnetic resonance imaging, including severe claustrophobia, based on clinical judgment. * Congenital or acquired deafness * Suicide risk, based on clinical judgment * Patient with moderate to severe intellectual disability, based on medical records * Patient with moderate to severe neurocognitive disorders, based on medical records * Patient receiving anticholinergic therapy (biperiden-Akineton, trihexyphenidyl-Artane, tropatepine-Lepticur) * Patient participating in an interventional study involving a drug or medical device, or a Category 1 RIPH within 3 months prior to inclusion * Person under judicial protection * Pregnant, parturient, or breastfeeding woman * Person unable to express consent

Primary outcome measure(s)

  • Resting state of functional connectivity of the inferior colliculi region with other regions of the auditory network between groups — Day 0
    Measured by MRI
  • Default mode network patterns between groups — Day 0
    Measured by MRI

Trial sites (1)

FacilityCityRegionStatus
CHU de Nîmes, Hôpital Universitaire Carémeau Nîmes France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07003529 on ClinicalTrials.gov ↗ ← All trials in France